Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony K Hall

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
BMJ (Clinical Research Ed.)|March 8, 2014
A new model for drug development using a multi-stakeholder consortiumAnthony K Hall
Intractable & Rare Diseases Research|October 25, 2014
The current status of orphan drug development in Europe and the USAnthony K Hall, Marilyn R Carlson
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 22, 2016
Prevalence of autosomal dominant polycystic kidney disease in the European UnionCynthia J Willey, Jaime D Blais, Anthony K Hall, et al.
Orphanet Journal of Rare Diseases|December 15, 2021
Clinical development innovation in rare diseases: lessons learned and best practices from the DevelopAKUre consortiumMattias Rudebeck, Ciarán Scott, Nicholas P Rhodes, et al.
JIMD Reports|March 17, 2015
Relationship Between Serum Concentrations of Nitisinone and Its Effect on Homogentisic Acid and Tyrosine in Patients with AlkaptonuriaBirgitta Olsson, Trevor F Cox, Eftychia E Psarelli, et al.
European Journal of Human Genetics : EJHG|March 26, 2015
Twelve novel HGD gene variants identified in 99 alkaptonuria patients: focus on 'black bone disease' in ItalyMartina Nemethova, Jan Radvanszky, Ludevit Kadasi, et al.
Annals of the Rheumatic Diseases|December 6, 2014
Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatmentLakshminarayan R Ranganath, Anna M Milan, Andrew T Hughes, et al.
The Lancet. Diabetes & Endocrinology|August 22, 2020
Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trialLakshminarayan R Ranganath, Eftychia Eirini Psarelli, Jean-Baptiste Arnoux, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
BMJ (Clinical Research Ed.)|March 8, 2014
A new model for drug development using a multi-stakeholder consortiumAnthony K Hall
Intractable & Rare Diseases Research|October 25, 2014
The current status of orphan drug development in Europe and the USAnthony K Hall, Marilyn R Carlson
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 22, 2016
Prevalence of autosomal dominant polycystic kidney disease in the European UnionCynthia J Willey, Jaime D Blais, Anthony K Hall, et al.
Orphanet Journal of Rare Diseases|December 15, 2021
Clinical development innovation in rare diseases: lessons learned and best practices from the DevelopAKUre consortiumMattias Rudebeck, Ciarán Scott, Nicholas P Rhodes, et al.
JIMD Reports|March 17, 2015
Relationship Between Serum Concentrations of Nitisinone and Its Effect on Homogentisic Acid and Tyrosine in Patients with AlkaptonuriaBirgitta Olsson, Trevor F Cox, Eftychia E Psarelli, et al.
European Journal of Human Genetics : EJHG|March 26, 2015
Twelve novel HGD gene variants identified in 99 alkaptonuria patients: focus on 'black bone disease' in ItalyMartina Nemethova, Jan Radvanszky, Ludevit Kadasi, et al.
Annals of the Rheumatic Diseases|December 6, 2014
Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatmentLakshminarayan R Ranganath, Anna M Milan, Andrew T Hughes, et al.
The Lancet. Diabetes & Endocrinology|August 22, 2020
Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trialLakshminarayan R Ranganath, Eftychia Eirini Psarelli, Jean-Baptiste Arnoux, et al.
Pageof 1